ProfileOfResearchers

Identified 1

1

TITLE: Doubling epirubicin dose intensity (100 mg/m(2) versus 50 mg/m(2)) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer
AUTHORS: Brufman, G; Colajori, E; Ghilezan, N; Lassus, M; Martoni, A; Perevodchikova, N; Tosello, C; Viaro, D; Zielinski, C; Krainer, M; Salzer, H; Schuller, J; Dittrich, C; Scheithauer, W; Zamagni, C; Ambrosini, G; Colucci, G; Gentilini, P; Zaniboni, A; Pacini, P; Bianco, R; Mustacchi, G; DAprile, M; DeMatteis, A; Oliveira, C; Jordaan, J; Gudgeon, A; VanZyl, J; Rakowsky, E; Inbar, M; Rath, P; Cohen, Y; Shani, A; Fried, G; Hegg, R; Neto, AB; Bader, G; Braga, RF; Vitoc, C; Puerto, VML; Valle, AE; Salazar, JD; Sanchez, JC; Villela, GM; Fountzilas, G; ...More
PUBLISHED: 1997, SOURCE: 19th ESMO Congress in ANNALS OF ONCOLOGY, VOLUME: 8, ISSUE: 2

INDEXED IN:

WOS

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service